Scientists have published a detailed plan for a future clinical trial. They want to see if combining two treatments helps improve thinking and memory problems in people with schizophrenia. The first treatment is called transcranial direct current stimulation (tDCS), a gentle form of brain stimulation. The second is cognitive remediation therapy, which is computer-based training for skills like memory and attention. The study will involve 120 adults with stable schizophrenia at a single clinic. Half will receive real brain stimulation before their cognitive training sessions, while the other half will receive a sham (fake) stimulation before the same training. The main goal is to measure changes in cognitive performance using a standard computer test battery. Researchers will also check for changes in schizophrenia symptoms and brain activity. The plan includes a follow-up assessment eight weeks after the treatment ends. Because this is only a study protocol, there are no results to report. We do not know if the combined treatment worked better than training alone, or if it caused any side effects. The main reason to be careful is that this document simply outlines what the researchers intend to do. It is not a report of findings. Readers should understand that this is a plan for research that has not yet been completed. The outcome of this trial could help inform future treatment approaches, but for now, there is no new evidence to consider.
Protocol published for trial testing tDCS plus cognitive training in schizophreniaResearchers plan trial to test brain stimulation plus cognitive training for schizophrenia
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Note: This is a protocol; no efficacy or safety results are available.
A published study protocol outlines a future randomized controlled trial. The trial will enroll 120 adults aged 18-65 years with clinically stable schizophrenia (DSM-5 criteria) at a single clinical center. Participants will be randomized to receive either active transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex or sham stimulation, both followed by cognitive remediation therapy using the RehaCom system.
The primary outcome is the change in cognitive performance measured with the CANTAB battery. Secondary outcomes include symptom severity (PANSS), global clinical status (CGI-S), and neurophysiological changes measured by EEG. Follow-up assessments are planned for 8 weeks after the intervention.
No results, effect sizes, or statistical data are reported, as this is a protocol for a trial that has not yet been conducted. Safety and tolerability data, including adverse events and discontinuations, are also not reported. The protocol does not list specific study limitations, but the key limitation is that it is a plan for research, not a report of findings. The practice relevance of this intervention cannot be assessed without trial results.
What this means for you:
This is a plan for a future study; no results on effectiveness or safety are available. More on Schizophrenia
GLP-1R exposure shows no causal link to most mental disorders except eating disorders
GLP-1 Receptor Agonists Show Mixed Links to Mental Health
This meta-analysis investigated the causal associations between GLP-1 receptor agonists and various mental health outcomes including anxiety…
New research explores how GLP-1 receptor agonists relate to conditions like anxiety and depression, finding no clear genetic link to most di…
Resting-state qEEG identifies distinct neurophysiological signatures in chronic schizophrenia compared to first-episode psychosis
Brain wave patterns help distinguish schizophrenia from early psychosis
This systematic review of 19 studies evaluates resting-state quantitative electroencephalography (qEEG) as a biomarker for schizophrenia and…
New research shows that specific brain wave changes can tell the difference between chronic schizophrenia and first-episode psychosis.
Virtual reality interventions significantly improve core symptoms and cognitive function in patients with schizophrenia
Virtual reality helps manage core symptoms of schizophrenia
This meta-analysis of 678 individuals with schizophrenia found that virtual reality (VR) interventions significantly improved overall psychi…
New data shows virtual reality can improve cognitive function and reduce key symptoms for people living with schizophrenia.
Public health interventions improve mental health in young people in LMICs: systematic review
Public health interventions improve mental health in young people in LMICs
A systematic review of 30 studies found that public health interventions, including digital health, improved mental health outcomes in young…
A review of 30 studies finds that public health interventions, including digital tools, can improve mental health in young people in low-inc…
View Original Abstract ↓
Background Cognitive impairment is a core feature of schizophrenia and a major determinant of functional disability. Executive deficits affect approximately 85% of patients and are associated with reduced activity in the prefrontal cortex (hypofrontality). Current pharmacological treatments show limited efficacy in improving cognition, highlighting the need for alternative therapeutic approaches. Combining non-invasive brain stimulation with cognitive remediation may enhance neuroplasticity and improve cognitive outcomes. Methods This prospective, randomized, double-blind, sham-controlled, parallel-group superiority clinical trial. A total of 120 adults aged 18-65 years with clinically stable schizophrenia diagnosed according to DSM-5 criteria will be enrolled at a single clinical center. Participants will be randomly assigned in a 1:1 ratio to receive either active transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex followed by cognitive remediation therapy (CRT) using the RehaCom system, or sham stimulation followed by the same cognitive training. Assessments will be conducted at three time points: prior to the intervention (V1), immediately after the intervention (V2), and during the follow-up visit 8 weeks after the intervention (V3). The primary outcome is change in cognitive performance measured with the CANTAB battery. Secondary outcomes include symptom severity assessed with the PANSS, global clinical status (CGI-S), and neurophysiological changes measured by EEG. Written informed consent will be obtained from all participants, and the study has received ethics committee approval. Discussion This trial will evaluate whether tDCS administered prior to cognitive training enhances cognitive improvement compared with cognitive training alone. The findings may inform the development of more effective interventions targeting cognitive deficits in schizophrenia. Trial registration ClinicalTrials.gov Identifier: NCT07273175. Registered on 25 November 2025.
PETRUSHKA decision-support tool reduced treatment discontinuation and improved symptoms in major depressive disorder
The Algorithm That Helps Doctors Pick the Right Antidepressant for You
Related in Psychiatry
Reducing social media use to 1 hour daily significantly reduces loneliness in youth
Limiting Social Media Use Reduces Loneliness in Youth with Anxiety
This randomized controlled trial of 219 youth with anxiety or depression found that limiting social media use to 1 hour per day for three we…
Youth with anxiety and depression felt less lonely after voluntarily limiting their social media use to one hour per day for three weeks.
GLP-1R exposure shows no causal link to most mental disorders except eating disorders
GLP-1 Receptor Agonists Show Mixed Links to Mental Health
This meta-analysis investigated the causal associations between GLP-1 receptor agonists and various mental health outcomes including anxiety…
New research explores how GLP-1 receptor agonists relate to conditions like anxiety and depression, finding no clear genetic link to most di…
Brief post-discharge interventions show reduced suicide outcomes in youth but lack specific autism-adapted data
Brief follow up programs may reduce suicide outcomes in youth
This systematic review of 24 studies examined brief post-discharge interventions for youth who have attempted suicide. While 8 studies showe…
New research looks at how quick safety planning and coping skills can help young people who have attempted suicide.
Open psychiatric wards improve depression scores and treatment adherence in hospitalized patients with depression
Open psychiatric wards may improve depression outcomes
This meta-analysis of 9 RCTs indicates that open psychiatric ward management leads to significantly lower SDS (MD -3.81) and HAMD (MD -0.99)…
A new analysis of 9 trials finds that open psychiatric wards may help reduce depression symptoms and boost treatment adherence in hospitaliz…
From Other Specialties
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …
Rapid advancements in imaging and blood-based biomarkers are transforming the diagnosis and management of ADRD
New guidelines help doctors tell delirium from dementia
This clinical guideline provides a narrative review on the evolving diagnostic and treatment landscape for Alzheimer's disease and related d…
Delirium is acute and fluctuating; dementia is chronic. New guidelines help doctors tell them apart.
ACTH and vigabatrin achieved full seizure control in a patient with Ververi-Brady syndrome
ACTH and Vigabatrin Show Promise for Rare Epilepsy Syndrome
This case report describes a 5-month-old male infant with Ververi-Brady syndrome and infantile epileptic spasms syndrome. The patient achiev…
A new gene variant linked to Ververi-Brady syndrome showed positive results when treated with a combination of ACTH and vigabatrin.